Undisclosed Parkinson's disease therapeutic / COSCIENS Biopharma, University of Wuerzburg - LARVOL DELTA

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease (GlobeNewswire) - "Aeterna Zentaris Inc...today provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals ('AIM Biologicals'), for the potential treatment of Parkinson’s Disease ('PD'). As previously announced, the data were presented at IMMUNOLOGY2022™, the annual event of the American Association of Immunologists, held on May 6-10, 2022 in Portland, Oregon....In a new, innovative mouse model of Parkinson’s disease, treatment with α-Synuclein specific AIM Biologicals showed a trend towards improved motoric function, as well as significant induction of regulatory T cells and rescue of substantia nigra neurons."

Preclinical • CNS Disorders • Parkinson's Disease